TY - JOUR
T1 - Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals
AU - Xiong, Chengjie
AU - Luo, Jingqin
AU - Wolk, David A.
AU - Shaw, Leslie M.
AU - Roberson, Erik D.
AU - Murchison, Charles F.
AU - Henson, Rachel L.
AU - Benzinger, Tammie L.S.
AU - Bui, Quoc
AU - Agboola, Folasade
AU - Grant, Elizabeth
AU - Gremminger, Emily N.
AU - Moulder, Krista L.
AU - Geldmacher, David S.
AU - Clay, Olivio J.
AU - Babulal, Ganesh
AU - Cruchaga, Carlos
AU - Holtzman, David M.
AU - Bateman, Randall J.
AU - Morris, John C.
AU - Schindler, Suzanne E.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to compare AD biomarkers in participants who identify their race as either Black or white. Plasma samples from 324 Black and 1,547 white participants underwent analysis with C2N Diagnostics’ PrecivityAD test for Aβ42 and Aβ40. Compared to white individuals, Black individuals had higher average plasma Aβ42/40 levels at baseline, consistent with a lower average level of amyloid pathology. Interestingly, this difference resulted from lower average levels of plasma Aβ40 in Black participants. Despite the differences, Black and white individuals had similar longitudinal rates of change in Aβ42/40, consistent with a similar rate of amyloid accumulation. Our results agree with multiple recent studies demonstrating a lower prevalence of amyloid pathology in Black individuals, and additionally suggest that amyloid accumulates consistently across both groups.
AB - Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to compare AD biomarkers in participants who identify their race as either Black or white. Plasma samples from 324 Black and 1,547 white participants underwent analysis with C2N Diagnostics’ PrecivityAD test for Aβ42 and Aβ40. Compared to white individuals, Black individuals had higher average plasma Aβ42/40 levels at baseline, consistent with a lower average level of amyloid pathology. Interestingly, this difference resulted from lower average levels of plasma Aβ40 in Black participants. Despite the differences, Black and white individuals had similar longitudinal rates of change in Aβ42/40, consistent with a similar rate of amyloid accumulation. Our results agree with multiple recent studies demonstrating a lower prevalence of amyloid pathology in Black individuals, and additionally suggest that amyloid accumulates consistently across both groups.
UR - http://www.scopus.com/inward/record.url?scp=85197415800&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-49859-w
DO - 10.1038/s41467-024-49859-w
M3 - Article
C2 - 38956096
AN - SCOPUS:85197415800
SN - 2041-1723
VL - 15
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 5539
ER -